OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free DGNOF Stock Alerts $0.20 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.20▼$0.2050-Day Range$0.20▼$0.3052-Week Range$0.19▼$0.43VolumeN/AAverage Volume8,881 shsMarket Capitalization$15.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsShort InterestStock AnalysisChartEarningsShort Interest Get DIAGNOS alerts: Email Address Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About DIAGNOS Stock (OTCMKTS:DGNOF)DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More DGNOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGNOF Stock News HeadlinesMarch 4, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsFebruary 29, 2024 | globenewswire.comDIAGNOS Welcomes Mr. Michael Braeuel to its Board of DirectorsMarch 18, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …February 27, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementFebruary 23, 2024 | globenewswire.comDiagnos Announces Variation in One Insider Ownership of Common SharesFebruary 21, 2024 | globenewswire.comDIAGNOS recognized as a Top TSX Venture Exchange CompanyDecember 8, 2023 | nytimes.comBest of 2023See More Headlines Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/18/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CUSIPN/A CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,880,000.00 Net Margins-1,553.79% Pretax Margin-1,032.49% Return on EquityN/A Return on Assets-297.10% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.79 Sales & Book Value Annual Sales$370,000.00 Price / Sales40.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-10.00Miscellaneous Outstanding Shares74,357,000Free FloatN/AMarket Cap$14.87 million OptionableNot Optionable Beta0.21 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, President & Executive ChairmanMr. Marc-André MassueVP of Finance, CFO & SecretaryMr. Yves-Stéphane CoutureChief Operating OfficerMr. Martin BelandDirector of MarketingKey CompetitorsNextech3D.AIOTCMKTS:NEXCFVictory Square TechnologiesOTCMKTS:VSQTFReliq Health TechnologiesOTCMKTS:RQHTFVoyager DigitalOTCMKTS:VYGVFPresto AutomationNASDAQ:PRSTView All Competitors DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed in 2024? DIAGNOS's stock was trading at $0.3050 at the start of the year. Since then, DGNOF stock has decreased by 34.4% and is now trading at $0.20. View the best growth stocks for 2024 here. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.04 million for the quarter. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DGNOF) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.